Completed PHASE1 INTERVENTIONAL 12-arm NCT02917200

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Moxifloxacin 400 mg/Day During 5 Days

Sponsor: Da Volterra

Conditions Healthy Subjects

Interventions DAV132 Moxifloxacin Negative control

Updated 6 times since 2017 Last updated: Sep 11, 2017 Started: May 11, 2016 Primary completion: Dec 2, 2016 Completion: Dec 2, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Subjects and is currently completed. Da Volterra leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE1

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Da Volterra

Data source: Da Volterra

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gières, France